G1T48 is a potential best-in-class oral selective estrogen receptor degrader (SERD) in development for the treatment of estrogen receptor-positive (ER+) breast cancer. Preclinical data have shown G1T48 to be more potent than Faslodex® (fulvestrant), currently the only FDA-approved SERD treatment. Unlike Faslodex®, which is administered as an intramuscular injection, G1T48 has the potential to significantly improve the patient experience with oral dosing. In 2018, we initiated a Phase 1/2a trial of G1T48 in estrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer (NCT03455270). We reported the first clinical data from this trial at the European Society for Medical Oncology (ESMO) Congress 2019 in September 2019. We are planning to initiate a Phase 3 trial of G1T48 in 2020.